IM Cannabis Corp Dossier
Qualitative Analysis
Business overview
IM Cannabis Corp. ("IMC") is an international medical cannabis company operating primarily in Israel and Germany. The company leverages an EU-GMP-certified production and distribution platform to supply premium medical cannabis to pharmacies. In Israel, IMC operates licensed pharmacies, an online retail platform, and home delivery services. In Germany, it distributes medical cannabis through its subsidiary Adjupharm GmbH. In mid-2026, IMC announced a strategic pivot to focus its operations on the Israeli market by entering into a non-binding letter of intent to sell its European activities (including Adjupharm) to Slil.com Holding Ltd., an entity controlled by CEO Oren Shuster, which is expected to reduce the company's debt by approximately C$10.5 million. Additionally, the company is exploring strategic diversification, having signed a letter of intent in March 2026 to acquire a 51% stake in Black Axe, a Polish defense and intelligence technology firm.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Actively evaluating strategic opportunities to expand operations into the United States cannabis market following the federal rescheduling directive. The company engaged SSC Advisors to provide strategic guidance and identify potential partners or acquirors.
Expected impact: Establishment of a commercial footprint in the high-value U.S. cannabis market.
Exploring and introducing additional business activities outside of medical cannabis to enhance long-term growth. This includes entering non-binding agreements to acquire defense and intelligence technology assets.
Expected impact: Strategic entry into high-growth defense and homeland security technology sectors, targeting cyber drone interception, satellite intelligence, imagery, and AI analytics.
Focusing on disciplined cost management, working capital discipline, and liquidity management. This includes the proposed divestiture of European operations to eliminate CAD$10.5 million in debt.
Expected impact: Reduction of debt burden, improvement of working capital, and stabilization of operating cash flows.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High. Under the non-binding LOI signed on June 18, 2026, IM Cannabis agreed to sell its European-focused assets (including German operations) to Slil.com (controlled by CEO Oren Shuster). Slil.com will assume approximately CAD$10,500,000 of debt, allowing the company to focus operations on Israel and improve cash flow.
Terms: Slil.com is expected to assume approximately CAD$10,500,000 of debt, including CAD$7,500,000 in retained liabilities and CAD$3,000,000 in certain short-term liabilities.
High. On March 17, 2026, the company signed a non-binding LOI to acquire a 51% equity interest in Blackaxe, a Polish defense-technology firm specializing in cyber drone interception, satellite intelligence, imagery, and AI analytics.
Terms: Not specified in the preliminary LOI.
Medium. On October 23, 2025, the company signed a non-binding indicative term sheet to acquire a 60% equity interest in a quantum computing bio data company to introduce additional business activities.
Terms: Aggregate consideration of up to USD$54 million, payable in a combination of cash, IMC shares, and potential earn-out payments tied to performance milestones.